Danaher Corporation enters the back half of May nursing an 18% one-month decline, with Q1 results that landed poorly and analysts still recalibrating where fair value sits.
The story this week is about the Street's reaction to earnings — and whether the reset has run far enough. DHR closed at $161.91 on Friday, down 5.4% for the week. The April 21 Q1 report triggered a 5.9% single-day drop that extended to a near 8.5% loss over the following five sessions. A secondary event on May 5 saw a much milder 0.5% first-day bounce, but the five-day drift was still negative, down 4.5%. That pattern — initial shock, brief stabilisation, renewed selling — has defined the last month of trading.
The analyst community absorbed the Q1 miss and responded with a coordinated round of target cuts, though crucially without changing ratings. Morgan Stanley kept its Overweight but trimmed to $255 from $270. Goldman Sachs maintained its Buy and cut to $230 from $265. UBS held Buy and took its target to $250. Barclays, Baird, and Guggenheim each followed the same script — positive on the name, cautious on the nearer-term outlook. That leaves the consensus mean price target near $248, implying roughly 53% upside from current levels. That gap is unusually wide, and it reflects genuine disagreement about how quickly Danaher's biotech and life sciences end-markets recover. Just yesterday, RBC reinstated coverage with an Outperform and a $200 target — more conservative than peers, but still above the current price. The RSI has dropped to 22, well into deeply oversold territory, which the Street has noted but not yet acted on.
The bears point to a challenging near-term operating picture. Only 46% of second-quarter 2025 performance obligations were expected to convert to revenue within twelve months, down from 48% the prior quarter. Biotech and life sciences revenue guidance fell short of expectations for Q3 2025. China exposure and foreign-exchange headwinds add further friction. Bulls counter with improving performance obligations totalling $4.9 billion in Q2 2025, a 4.5% life sciences growth projection for Q4, and a respiratory segment poised to generate $450–500 million in Q4. The EV/EBITDA multiple has compressed to around 15.7x — lower than a month ago, though the forward-year EPS growth ranking sits at the 100th percentile of the universe, suggesting the earnings trajectory remains intact even if the near-term top line is lumpy.
Short positioning tells a fairly calm story, one that sits in sharp contrast to the scale of the price decline. Short interest as a percentage of the free float is only 1.2%, having roughly doubled over the past month from a low base of around 0.5%. Even at this pace of accumulation, the level remains low. Days to cover is under two. Borrowing costs have collapsed from around 0.45%–0.67% in April to just 0.07% — essentially the GC rate. Availability is ample. The lending market is not generating any squeeze pressure, and the borrow-cost crash suggests short sellers are not competing aggressively for the stock. Peers have also sold off hard: TMO dropped 5.7% on the week, RGEN fell nearly 17%, and TECH shed 10.5%, confirming broad sector pressure rather than a DHR-specific dislocation.
Options positioning has turned notably less defensive over the past week, which cuts against the prevailing price action. The put/call ratio has dropped to 0.82, running about 1.2 standard deviations below its 20-day average of 0.97. As recently as May 5–8, the PCR was running above 1.18 — the most defensive it had been in weeks. That reversal, with calls now commanding a larger share of options activity as the stock trades near a 52-week low, is the most interesting tension in the current setup. Institutional ownership remains firm: Capital Research, T. Rowe, FMR, Wellington, and JPMorgan Asset Management all added materially in recent reporting periods. Insider activity has been confined to routine small-lot sales — nothing that changes the directional read.
With no next earnings event yet scheduled and the stock trading at a 28% YTD loss, the key question for the coming sessions is whether the options market's recent shift toward calls reflects genuine bottom-fishing conviction or simply a mechanical unwinding of the downside hedges that accumulated ahead of results.
See the live data behind this article on ORTEX.
Open DHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
